A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors
Latest Information Update: 21 Oct 2024
Price :
$35 *
At a glance
- Drugs INCB-099318 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 16 Oct 2024 Status changed from active, no longer recruiting to discontinued.
- 15 Aug 2023 Planned End Date changed from 30 Jun 2024 to 20 Jun 2026.
- 15 Aug 2023 Planned primary completion date changed from 30 Jun 2024 to 30 Jan 2026.